Citations

Mayo Clinic

Showing 10 of 108537 citations.

Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer
Huober, Jens , Park, Inhae, Campone, Mario , Chen, Shin‐Cheh , Manso, Luis Manual, Freedman, Orit, Saha, Abhijoy , Hal, Gertjan van , Shahir, Ashwin, O’Shaughnessy, Joyce , Tolaney, Sara M. , Hurvitz, Sara A. , Manso, Luís , Manso Sanchez, Luis , Goetz, Matthew P. , Toi, Masakazu , Sohn, Joohyuk , Trédan, Olivier , Paluch–Shimon, Shani , Andre, Valerie, Iwata, Hiroji , Johnston, Stephen , Pivot, Xavier B. , Llombart‐Cussac, Antonio

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: GS01-12-GS01-12

10.1158/1538-7445.sabcs23-gs01-12 Get It

Abstract Background: Abemaciclib is approved both for high-risk early breast cancer as well as advanced breast cancer (ABC) in the first- and second-line setting. In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with HR+, HER2- ABC with disease progression on prior endocrine therapy (ET). In MONARCH 3, the addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) significantly improved PFS (HR, 0.540; 95% CI, 0.418-0.698; p=0.000002) as initial therapy in HR+, HER2- ABC. At the last interim OS analysis (~252 events, at 5.8 years follow-up [FU]), a numerically favorable median OS difference (12.6 months) was observed (HR, 0.754; 95% CI, 0.584-0.974; p=0.0301, non-significant [NS]). Here, we present the final OS analysis of MONARCH 3 (NCT02246621). Methods: MONARCH 3 is a randomized, double-blind, Phase 3 study of abemaciclib + NSAI (anastrozole or letrozole) vs placebo + NSAI in postmenopausal women with HR+, HER2- ABC without prior systemic therapy in the advanced setting. OS was a gated secondary endpoint and chemotherapy-free survival (CFS) an exploratory endpoint. Final OS analysis was planned after approximately 315 OS events had occurred in the intent-to-treat (ITT) population with a split alpha between the ITT population and the subgroup with visceral disease (sVD) according to a prespecified graphical testing scheme. Kaplan-Meier method and stratified Cox proportional hazards models were used for time-to-event analyses. All reported p-values are two-sided. Results A total of 493 women were randomized 2:1 to receive abemaciclib + NSAI (n=328) or placebo + NSAI (n=165). After a median FU of 8.1 years, 7% of patients were still receiving treatment in the abemaciclib arm vs 3% in the placebo arm. In the ITT population, 314 OS events were observed (198 deaths among 328 patients [60%] in the abemaciclib arm and 116 among 165 [70%] in the placebo arm; HR, 0.804; 95% CI, 0.637-1.015; p=0.0664, NS). Median OS was 66.8 months in the abemaciclib arm and 53.7 months in the placebo arm, a numerical difference of 13.1 months in the ITT population. In the sVD, 178 events were observed (113 deaths among 173 patients [65%] in the abemaciclib arm and 65 among 90 [72%] in the placebo arm; HR, 0.758; 95% CI, 0.558-1.030; p=0.0757, NS). Median OS was 63.7 months in the abemaciclib arm and 48.8 months in the placebo arm, a numerical difference of 14.9 months in the sVD. Consistent OS differences were observed across prespecified subgroups. PFS benefit was sustained (median 29.0 vs 14.8 months; HR, 0.535; 95% CI, 0.429-0.668; nominal p<0.0001) with substantial difference in 6-year PFS rates (23.3% vs 4.3% for abemaciclib vs placebo). CFS was also improved with abemaciclib vs placebo (median 46.7 vs 30.6 months; HR, 0.693; 95% CI, 0.557-0.863; nominal p=0.0010). No new safety signals were observed with longer term use. Conclusion In patients with HR+, HER2- ABC, abemaciclib in combination with a NSAI resulted in numerically longer OS compared to NSAI alone; however, statistical significance was not reached after a median FU of 8.1 years. The clinically meaningful improvement in median OS (>13 months) combined with the sustained significant improvement in median PFS (>14 months) and substantial extension in median CFS (>16 months) continue to support the use of abemaciclib in combination with NSAI as first-line therapy in ABC. Citation Format: Matthew Goetz, Masakazu Toi, Jens Huober, Joo Hyuk Sohn, Olivier Trédan, Inhae Park, Mario Campone, Shin-Cheh Chen, Luis Manual Manso, Shani Paluch-Shimon, Orit C. Freedman, Valerie Andre, Abhijoy Saha, Gertjan van Hal, Ashwin Shahir, Hiroji Iwata, Stephen RD Johnston, Joyce O'Shaughnessy, Xavier Pivot, Sara Tolaney, Sara Hurvitz, Antonio Llombart. MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr GS01-12.
Automated Analysis of Split Kidney Function from CT Scans Using Deep Learning and Delta Radiomics
Correa, Ramón , Jeong, Jiwoong , Patel, Bhavik N. , Banerjee, Imon , Banerjee, Imon, Abdul‐Muhsin, Haidar , Correa-Medero, Ramon Luis , Banerjee, Imon , Banerjee, Imon

Journal of Endourology | May 2, 2024 | Volume: 38 | Issue: 8 | Pages: 817-823

10.1089/end.2023.0488 | PMID 38695176 Get It

Background: Differential kidney function assessment is an important part of preoperative evaluation of various urological interventions. It is obtained through dedicated nuclear medical imaging and is not yet implemented through conventional Imaging. Objective: We assess if differential kidney function can be obtained through evaluation of contrast-enhanced computed tomography(CT) using a combination of deep learning and (2D and 3D) radiomic features. Methods: All patients who underwent kidney nuclear scanning at Mayo Clinic sites between 2018–2022 were collected. CT scans of the kidneys were obtained within a 3-month interval before or after the nuclear scans were extracted. Patients who underwent a urological or radiological intervention within this time frame were excluded. A segmentation model was used to segment both kidneys. 2D and 3D radiomics features were extracted and compared between the two kidneys to compute delta radiomics and assess its ability to predict differential kidney function. Performance was reported using receiver operating characteristics, sensitivity, and specificity. Results: Studies from Arizona & Rochester formed our internal dataset ( n = 1,159). Studies from Florida were separately processed as an external test set to validate generalizability. We obtained 323 studies from our internal sites and 39 studies from external sites. The best results were obtained by a random forest model trained on 3D delta radiomics features. This model achieved an area under curve (AUC) of 0.85 and 0.81 on internal and external test sets, while specificity and sensitivity were 0.84,0.68 on the internal set, 0.70, and 0.65 on the external set. Conclusion: This proposed automated pipeline can derive important differential kidney function information from contrast-enhanced CT and reduce the need for dedicated nuclear scans for early-stage differential kidney functional assessment. Clinical Impact: We establish a machine learning methodology for assessing differential kidney function from routine CT without the need for expensive and radioactive nuclear medicine scans.
Exploring COVID‐19 census burdens by US hospital characteristics: Implications of quality reporting at rural and critical access hospitals
Ugwuowo, Ugochukwu , Meier, Sarah , Franco, Pablo Moreno , Dowdy, Sean C. , Pollock, Benjamin D. , Noe, Katherine H. , Pollock, Benjamin D , Moreno Franco, Pablo

The Journal of Rural Health | May 2, 2024 | Volume: 40 | Issue: 3 | Pages: 485-490

10.1111/jrh.12841 | PMID 38693658 Get It

AbstractPurposeBy assessing longitudinal associations between COVID‐19 census burdens and hospital characteristics, such as bed size and critical access status, we can explore whether pandemic‐era hospital quality benchmarking requires risk‐adjustment or stratification for hospital‐level characteristics.MethodsWe used hospital‐level data from the US Department of Health and Human Services including weekly total hospital and COVID‐19 censuses from August 2020 to August 2023 and the 2021 American Hospital Association survey. We calculated weekly percentages of total adult hospital beds containing COVID‐19 patients. We then calculated the number of weeks each hospital spent at Extreme (≥20% of beds occupied by COVID‐19 patients), High (10%–19%), Moderate (5%–9%), and Low (<5%) COVID‐19 stress. We assessed longitudinal hospital‐level COVID‐19 stress, stratified by 15 hospital characteristics including joint commission accreditation, bed size, teaching status, critical access hospital status, and core‐based statistical area (CBSA) rurality.FindingsAmong n = 2582 US hospitals, the median(IQR) weekly percentage of hospital capacity occupied by COVID‐19 patients was 6.7%(3.6%–13.0%). 80,268/213,383 (38%) hospital‐weeks experienced Low COVID‐19 census stress, 28% Moderate stress, 22% High stress, and 12% Extreme stress. COVID‐19 census burdens were similar across most hospital characteristics, but were significantly greater for critical access hospitals.ConclusionsUS hospitals experienced similar COVID‐19 census burdens across multiple institutional characteristics. Evidence‐based inclusion of pandemic‐era outcomes in hospital quality reporting may not require significant hospital‐level risk‐adjustment or stratification, with the exception of rural or critical access hospitals, which experienced differentially greater COVID‐19 census burdens and may merit hospital‐level risk‐adjustment considerations.
Heart Transplantation for Ebstein Anomaly due to Late Surgical Presentation
Leng, Tomas , Dearani, Joseph A. , Stephens, Elizabeth H. , Johnson, Jonathan N. , Dearani, Joseph A.

World Journal for Pediatric and Congenital Heart Surgery | May 2, 2024 | Volume: 15 | Issue: 5 | Pages: 658-660

10.1177/21501351241239305 | PMID 38693812 Get It

Ebstein anomaly is a myopathy of the right ventricle characterized by failure of tricuspid valve delamination with accompanying tricuspid regurgitation. Its rarity, considerable anatomic variability, and frequent absence of symptoms can make the timing of surgery challenging. Contemporary tricuspid repair techniques can be performed with low mortality and bidirectional cavopulmonary anastomosis reduces the risk of operation when right ventricular function is poor. Here, we present a patient who presented late for surgery, failed high-risk conventional surgery and required heart transplantation.
Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta‐analysis and Systematic Review
Garg, Shivani , Sweet, Nadia, Boderman, Brianna, Montes, Daniel , Walunas, Theresa L. , Ramsey‐Goldman, Rosalind , Khosroshahi, Arezou , Lim, S. Sam , Bartels, Christie M. , Walunas, Theresa L , Lim, S Sam , Bartels, Christie M , Garg, Shivani , Ramsey-Goldman, Rosalind , Astor, Brad C.

Arthritis Care & Research | May 2, 2024 | Volume: 76 | Issue: 9 | Pages: 1232-1245

10.1002/acr.25359 | PMID 38693617 Get It

Objective Social determinants of health (SDoH) likely contribute to outcome disparities in lupus nephritis (LN). Understanding the overall burden and contribution of each domain could guide future health equity–focused interventions to improve outcomes and reduce disparities in LN. Objectives of this meta‐analysis were to 1) determine the association of overall SDoH and specific SDoH domains on LN outcomes and 2) develop a framework for the multidimensional impact of SDoH on LN outcomes. Methods We performed a comprehensive search of studies measuring associations between SDoH and LN outcomes. We examined pooled odds of poor LN outcomes including death, end‐stage kidney disease, or cardiovascular disease in patients with and without adverse SDoH. Additionally, we calculated the pooled odds ratios of outcomes by four SDoH domains: individual (eg, insurance), health care (eg, fragmented care), community (eg, neighborhood socioeconomic status), and health behaviors (eg, smoking). Results Among 531 screened studies, 31 meeting inclusion criteria and 13 with raw data were included in meta‐analysis. Pooled odds of poor outcomes were 1.47‐fold higher in patients with any adverse SDoH. Patients with adverse SDoH in individual and health care domains had 1.64‐fold and 1.77‐fold higher odds of poor outcomes. We found a multiplicative impact of having two or more adverse SDoH on LN outcomes. Black patients with public insurance and fragmented care had 12‐fold higher odds of poor LN outcomes. Conclusion Adverse SDoH is associated with poor LN outcomes. Having two or more adverse SDoH, specifically in different SDoH domains, had a multiplicative impact leading to worse LN outcomes, widening disparities. image
Post‐diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis
Markozannes, Georgios , Balducci, Katia, Vieira, Rita , Kiss, Š., Aune, Dagfinn , Greenwood, Darren C. , Copson, Ellen , Bours, Martijn J.L. , Demark‐Wahnefried, Wendy , May, Anne M. , Skinner, Roderick , Tjønneland, Anne , Velikova, Galina , Chowdhury, Rajiv , Hill, L. Robert, Seidell, Jaap, Krebs, John R., Cross, Amanda J. , Chan, Doris S.M. , Markozannes, Georgios , Aune, Dagfinn , Demark-Wahnefried, Wendy , Tsilidis, Konstantinos K , Chan, Doris S M , Tjønneland, Anne , Becerra‐Tomás, Nerea , Cariolou, Margarita , Dossus, Laure , Renehan, Andrew G. , Hudson, Melissa M. , Steindorf, Karen , Baskin, Monica L. , Hill, Lynette, Lewis, Sarah J., Seidell, Jacob C. , Weijenberg, Matty P. , Tsilidis, Konstantinos K.

International Journal of Cancer | May 2, 2024 | Volume: 155 | Issue: 3 | Pages: 400-425

10.1002/ijc.34905 | PMID 38692659 Get It

AbstractThe adiposity influence on colorectal cancer prognosis remains poorly characterised. We performed a systematic review and meta‐analysis on post‐diagnosis adiposity measures (body mass index [BMI], waist circumference, waist‐to‐hip ratio, weight) or their changes and colorectal cancer outcomes. PubMed and Embase were searched through 28 February 2022. Random‐effects meta‐analyses were conducted when at least three studies had sufficient information. The quality of evidence was interpreted and graded by the Global Cancer Update Programme (CUP Global) independent Expert Committee on Cancer Survivorship and Expert Panel. We reviewed 124 observational studies (85 publications). Meta‐analyses were possible for BMI and all‐cause mortality, colorectal cancer‐specific mortality, and cancer recurrence/disease‐free survival. Non‐linear meta‐analysis indicated a reverse J‐shaped association between BMI and colorectal cancer outcomes (nadir at BMI 28 kg/m2). The highest risk, relative to the nadir, was observed at both ends of the BMI distribution (18 and 38 kg/m2), namely 60% and 23% higher risk for all‐cause mortality; 95% and 26% for colorectal cancer‐specific mortality; and 37% and 24% for cancer recurrence/disease‐free survival, respectively. The higher risk with low BMI was attenuated in secondary analyses of RCTs (compared to cohort studies), among studies with longer follow‐up, and in women suggesting potential methodological limitations and/or altered physiological state. Descriptively synthesised studies on other adiposity‐outcome associations of interest were limited in number and methodological quality. All the associations were graded as limited (likelihood of causality: no conclusion) due to potential methodological limitations (reverse causation, confounding, selection bias). Additional well‐designed observational studies and interventional trials are needed to provide further clarification.
Glycerol Kinase Deficiency with Increased Triglycerides and Weight Gain: Pseudo or Real?
Bernard, Paul E. , Meeusen, Jeffrey W. , Militello, Leah , El-Khoury, Joe M , Meeusen, Jeffrey, El-Khoury, Joe M , Jiao, Jingjing

Clinical Chemistry | May 2, 2024 | Volume: 70 | Issue: 5 | Pages: 703-706

10.1093/clinchem/hvae032 | PMID 38692658 Get It

Post‐diagnosis physical activity and sedentary behaviour and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis
Markozannes, Georgios , Balducci, Katia, Vieira, Rita , Kiss, Š., Aune, Dagfinn , Greenwood, Darren C. , Copson, Ellen , Bours, Martijn J.L. , Demark‐Wahnefried, Wendy , May, Anne M. , Skinner, Roderick , Tjønneland, Anne , Velikova, Galina , Chowdhury, Rajiv , Hill, L. Robert, Seidell, Jaap, Krebs, John R., Cross, Amanda J. , Chan, Doris S.M. , Aune, Dagfinn , Demark-Wahnefried, Wendy , Tsilidis, Konstantinos K , Chan, Doris S M , Tjønneland, Anne , Markozannes, Georgios , Becerra‐Tomás, Nerea , Cariolou, Margarita , Gunter, Marc J. , Renehan, Andrew G. , Hudson, Melissa M. , Steindorf, Karen , Baskin, Monica L. , Hill, Lynette, Lewis, Sarah J., Seidell, Jacob C. , Weijenberg, Matty P. , Tsilidis, Konstantinos K.

International Journal of Cancer | May 2, 2024 | Volume: 155 | Issue: 3 | Pages: 426-444

10.1002/ijc.34903 | PMID 38692650 Get It

AbstractLow physical activity and high sedentary behaviour have been clearly linked with colorectal cancer development, yet data on their potential role in colorectal cancer survival is limited. Better characterisation of these relationships is needed for the development of post‐diagnosis physical activity and sedentary behaviour guidance for colorectal cancer survivors. We searched PubMed and Embase through 28 February 2022 for studies assessing post‐diagnosis physical activity, and/or sedentary behaviour in relation to all‐cause and cause‐specific mortality and recurrence after colorectal cancer diagnosis. Total and recreational physical activity were assessed overall and by frequency, duration, intensity, and volume using categorical, linear, and non‐linear dose–response random‐effects meta‐analyses. The Global Cancer Update Programme (CUP Global) independent Expert Committee on Cancer Survivorship and Expert Panel interpreted and graded the likelihood of causality. We identified 16 observational studies on 82,220 non‐overlapping patients from six countries. Physical activity was consistently inversely associated with colorectal cancer morbidity and mortality outcomes, with 13%–60% estimated reductions in risk. Sedentary behaviour was positively associated with all‐cause mortality. The evidence had methodological limitations including potential confounding, selection bias and reverse causation, coupled with a limited number of studies for most associations. The CUP Global Expert panel concluded limited‐suggestive evidence for recreational physical activity with all‐cause mortality and cancer recurrence. Total physical activity and its specific domains and dimensions, and sedentary behaviour were all graded as limited‐no conclusion for all outcomes. Future research should focus on randomised trials, while observational studies should obtain objective and repeated physical activity measures and better adjustment for confounders.
Post‐diagnosis adiposity, physical activity, sedentary behaviour, dietary factors, supplement use and colorectal cancer prognosis: Global Cancer Update Programme (CUP Global) summary of evidence grading
Tsilidis, Konstantinos K. , Balducci, Katia, Vieira, Rita , Kiss, Š., Aune, Dagfinn , Greenwood, Darren C. , González‐Gil, Esther M. , Brockton, Nigel T. , Mitrou, Panagiota , Musuwo, Nicole , Copson, Ellen , Bours, Martijn J.L. , Demark‐Wahnefried, Wendy , May, Anne M. , Skinner, Roderick , Tjønneland, Anne , Velikova, Galina , Chowdhury, Rajiv , Hill, L. Robert, Seidell, Jaap, Krebs, John R., Cross, Amanda J. , Chan, Doris S.M. , Aune, Dagfinn , Demark-Wahnefried, Wendy , Chan, Doris S M , Tjønneland, Anne , Tsilidis, Konstantinos K , Markozannes, Georgios , Becerra‐Tomás, Nerea , Cariolou, Margarita , Dossus, Laure , Gunter, Marc J. , Allen, Kate , Croker, Helen A. , Gordon-Dseagu, Vanessa , Wiseman, Martin J , Renehan, Andrew G. , Hudson, Melissa M. , Steindorf, Karen , Baskin, Monica L. , Hill, Lynette, Lewis, Sarah J., Seidell, Jacob C. , Weijenberg, Matty P.

International Journal of Cancer | May 2, 2024 | Volume: 155 | Issue: 3 | Pages: 471-485

10.1002/ijc.34904 | PMID 38692587 Get It

AbstractBased on the World Cancer Research Fund Global Cancer Update Programme, we performed systematic reviews and meta‐analyses to investigate the association of post‐diagnosis adiposity, physical activity, sedentary behaviour, and dietary factors with colorectal cancer prognosis. We searched PubMed and Embase until 28th February, 2022. An independent expert committee and expert panel graded the quality of evidence. A total of 167 unique publications were reviewed, and all but five were observational studies. The quality of the evidence was graded conservatively due to the high risk of several biases. There was evidence of non‐linearity in the associations between body mass index and colorectal cancer prognosis. The associations appeared reverse J‐shaped, and the quality of this evidence was graded as limited (likelihood of causality: limited‐no conclusion). The evidence on recreational physical activity and lower risk of all‐cause mortality (relative risk [RR] highest vs. lowest: 0.69, 95% confidence interval [CI]: 0.62–0.77) and recurrence/disease‐free survival (RR: 0.80, 95% CI: 0.70–0.92) was graded as limited‐suggestive. There was limited‐suggestive evidence for the associations between healthy dietary and/or lifestyle patterns (including diets that comprised plant‐based foods), intake of whole grains and coffee with lower risk of all‐cause mortality, and between unhealthy dietary patterns and intake of sugary drinks with higher risk of all‐cause mortality. The evidence for other exposures on colorectal cancer outcomes was sparse and graded as limited‐no conclusion. Analyses were conducted excluding cancer patients with metastases without substantial changes in the findings. Well‐designed intervention and cohort studies are needed to support the development of lifestyle recommendations for colorectal cancer patients.